A Prospective Study Evaluating IOP Changes after Switching from a Therapy with Prostaglandin Eye Drops Containing Preservatives to Nonpreserved Tafluprost in Glaucoma Patients

<table>Graph showing IOP at each time point of the daily curve at baseline (PGAs) and after switching to tafluprost. *<svg height="11.25" id="M24" style="vertical-align:-0.30096pt" version="1.1" viewbox="0 0 56.150002 11.25" width="56.150002" xmlns="http://www.w3.org/2000/svg">
<g transform="matrix(1.25,0,0,-1.25,0,11.25)">
<g transform="translate(72,-63)">
<text transform="matrix(1,0,0,-1,-71.95,63.35)">
<tspan style="font-size: 12.50px; " x="0" y="0">𝑃</tspan>
<tspan style="font-size: 12.50px; " x="10.890113" y="0">&gt;</tspan>
<tspan style="font-size: 12.50px; " x="22.930502" y="0">0</tspan>
<tspan style="font-size: 12.50px; " x="29.182001" y="0">.</tspan>
<tspan style="font-size: 12.50px; " x="32.307751" y="0">0</tspan>
<tspan style="font-size: 12.50px; " x="38.559254" y="0">5</tspan>
</text>
</g>
</g>
</svg> from the comparison of tafluprost time point with the corresponding PGAs time point. (Curve of PGAs are prestudy, whereas curve of tafluprost is after dosing.) </table>

The Scientific World Journal

fig1

Figure 1

Figure 1: A Prospective Study Evaluating IOP Changes after Switching from a Therapy with Prostaglandin Eye Drops Containing Preservatives to Nonpreserved Tafluprost in Glaucoma Patients 

Figure 1 | A Prospective Study Evaluating IOP Changes after Switching from a Therapy with Prostaglandin Eye Drops Containing Preservatives to Nonpreserved Tafluprost in Glaucoma Patients 